ACE2 and diabetic kidney disease: In support of this concept, we and others have shown that genetic deletion or pharmacologic inhibition of ACE2 worsens experimental kidney disease including diabetic nephropathy and unilateral ureteral obstruction, while administration of recombinant ACE2 or over-expression of ACE2 improves kidney injury [18]–[23].